Skip to main content
UniHealth

Doctor search

Lamson DO Nguyen, PA

Physician Assistant · Pleasanton

NPI 1255954988

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2

Offices

2 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Lamson DO Nguyen’s office at (650) 723-4000 to ask if they take your plan before you enroll.

California Medical Board record

Licence G58377 · Cancelled

Licence status: Cancelled · since 1986 · University of California, Irvine College of Medicine.

License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.

Matched on the licence number without its letter prefix; check the name before relying on it.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$589,689

Medicare paid this office $589,689 for 238 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Injection, denosumab, 1 mg15$35,186None
Return visit (30+ min)141$27,910$101
Injection, darbepoetin alfa, 1 microgram (non-esrd use)11$13,729None
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg11$7,504None
Administration of chemotherapy into vein, 1 hour or less36$6,686$115
See all 17 services
Every Original Medicare service billed
Injection, denosumab, 1 mg15$35,186None
Return visit (30+ min)141$27,910$101
Injection, darbepoetin alfa, 1 microgram (non-esrd use)11$13,729None
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg11$7,504None
Administration of chemotherapy into vein, 1 hour or less36$6,686$115
Long return visit (40+ min)37$5,575$136
Short return visit (20+ min)55$5,429$68
Administration of additional new drug or substance into vein, 1 hour or less12$1,361$57
Injection of additional new drug or substance into vein28$1,301$13
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less14$1,299$56
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count96$1,212$8
Injection of drug or substance under skin or into muscle48$877$12
Injection, palonosetron hcl, 25 mcg19$238None
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's12$151$13
Insertion of needle into vein for collection of blood sample13$104$8
Injection, dexamethasone sodium phosphate, 1 mg21$33None
Injection, diphenhydramine hcl, up to 50 mg16$18None

Who their Medicare patients are

238 Original Medicare patients in 2024. Average age 76 · Under 65 7% · 85 and older 21% · Women 70% · Also on Medicaid 17% · Health risk score 2.33. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.

Conditions among them: High blood pressure 75% · Cancer 58% · Chronic kidney disease 47% · Diabetes 28% · Depression 26% · Coronary heart disease 25% · Atrial fibrillation 22% · COPD 21% · Heart failure 18% · Dementia 8% · Stroke 7%.

The office billed $2,867,250, Medicare allowed $742,146 and paid $589,689; for 44,735 services of 83 kinds; $532,493 of it was for drugs given in the office and $57,196 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202423844,735762.33$2,867,250$589,689
2023228137,875772.20$8,997,231$1,914,897

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 23 services

Original Medicare services billed in 2023
Injection, pembrolizumab, 1 mg11$297,324None
Injection, denosumab, 1 mg34$110,488None
Injection, darbepoetin alfa, 1 microgram (non-esrd use)28$51,526None
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg15$33,654None
Administration of chemotherapy into vein, 1 hour or less52$23,322$117
Injection, ferric carboxymaltose, 1 mg20$22,459None
Return visit (30+ min)79$11,834$102
Long return visit (40+ min)39$5,685$142
Injection of additional new drug or substance into vein40$4,531$13
Short return visit (20+ min)45$3,843$73
Administration of additional new drug or substance into vein, 1 hour or less16$2,983$57
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count137$2,915$8
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less27$2,567$57
Injection of drug or substance under skin or into muscle77$2,305$12
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle18$1,780$30
Administration of chemotherapy into vein, each additional hour16$1,513$24
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less13$1,060$25
Injection, palonosetron hcl, 25 mcg23$700None
Application of on-body injector for under skin injection14$614$16
Injection of drug or substance into vein16$598$31
Injection, zoledronic acid, 1 mg11$290None
Injection, dexamethasone sodium phosphate, 1 mg29$119None
Injection, diphenhydramine hcl, up to 50 mg25$57None

Medicaid work

$18,222 in 2023

Medicaid paid $18,222 for 212 billed services this clinician did in 2023, up to 33 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2023
Return visit (30+ min)46$5,986
Short return visit (20+ min)55$4,093
New patient visit (45+ min)24$3,613
New patient visit (30+ min)29$2,962
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r13$619
Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])15$528
SARSCOV CORONAVIRUS AG IA13$375
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy17$47
Medicaid work by year
2023212833$18,222
2022411538$14,450
20211,1896111$31,421
202072232$2,278
See the largest Medicaid services in earlier years

2022

Largest Medicaid services in 2022
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r160$6,963
Short return visit (20+ min)161$4,668
New patient visit (30+ min)57$2,652
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r215$125
Handling and/or conveyance of specimen for transfer from physician office to laboratory18$42

2021

Largest Medicaid services in 2021
New patient visit (30+ min)474$21,198
Short return visit (20+ min)230$6,666
Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique89$2,260
Handling and/or conveyance of specimen for transfer from physician office to laboratory371$935
Short return visit13$296
SARSCOV CORONAVIRUS AG IA12$65

2020

Largest Medicaid services in 2020
New patient visit (30+ min)47$2,220
Handling and/or conveyance of specimen for transfer from physician office to laboratory25$58

Drugs they prescribed that Part D paid

$1,849,623

Pharmacies billed $1,849,623 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 2% of their Part D prescriptions (18 of 807) in 2024. Above the middle of the specialty; the typical physician assistant clinician is at 1%.

621 generic and 186 brand-name prescriptions · $1,849,623 in drug cost · 26 antibiotic prescriptions to 17 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Ibrance23$430,739$18,728
Revlimid14$254,625$18,188
Nubeqa15$208,842$13,923
Xtandi13$173,377$13,337
Xarelto50$50,165$1,003
See all 21 drugs
Every Part D drug this clinician prescribed
Ibrance23$430,739$18,728
Revlimid14$254,625$18,188
Nubeqa15$208,842$13,923
Xtandi13$173,377$13,337
Xarelto50$50,165$1,003
Eliquis21$23,398$1,114
Exemestane21$3,382$161
Abiraterone Acetate11$1,877$171
Letrozole61$1,414$23
Anastrozole40$1,131$28
Hydroxyurea26$874$34
Dexamethasone30$622$21
Prochlorperazine Maleate43$489$11
Acyclovir16$357$22
Levothyroxine24$334$14
Ondansetron31$273$9
Omeprazole17$258$15
Lidocaine-Prilocaine17$216$13
Gabapentin28$192$7
Lorazepam17$144$8
Alendronate28$142$5

Year by year

Part D prescribing by year
20248072212% (18)23%$1,849,623
20236552536% (37)None$742,209
20227653NoneNone$1,516
202143280% (0)None$366

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 16 drugs

Part D drugs prescribed in 2023
Xarelto27$22,959$850
Eliquis27$20,056$743
Letrozole26$845$32
Hydroxyurea11$814$74
Anastrozole26$798$31
Prochlorperazine Maleate39$460$12
Alendronate23$336$15
Hydrocodone-Acetaminophen16$316$20
Ondansetron32$302$9
Cephalexin12$242$20
Dexamethasone11$173$16
Prednisone18$167$9
Mupirocin13$129$10
Levothyroxine14$123$9
Sulfamethoxazole-Trimethoprim15$123$8
Lorazepam13$97$7

2022: 1 drug

Part D drugs prescribed in 2022
Sulfamethoxazole-Trimethoprim11$37$3

Money from drug and device companies

$146 in 2025

Industry payments by year
202525None$146
2024914None$389
202378None$197

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Daiichi SankyoEnhertu$118
4 payments
  • Meals for Datroway · 2025-10-15 · $47
  • Meals for Enhertu · 2025-06-11 · $25
  • Meals for Enhertu · 2025-05-20 · $20
  • Meals for Enhertu · 2025-05-06 · $27
AbbvieImbruvica$28
1 payment
  • Meals for Imbruvica · 2025-12-04 · $28
See all 5 published payments
Every published payment
AbbvieMeals · 2025-12-04Imbruvica$28
Daiichi SankyoMeals · 2025-10-15Datroway$47
Daiichi SankyoMeals · 2025-06-11Enhertu$25
Daiichi SankyoMeals · 2025-05-20Enhertu$20
Daiichi SankyoMeals · 2025-05-06Enhertu$27
See earlier years (2024, 2023)

2024: $389

Payments by company in 2024
Daiichi SankyoEnhertu$178
6 payments
  • Meals for Enhertu · 2024-10-17 · $7
  • Education for Enhertu · 2024-10-17 · $99
  • Meals for Enhertu · 2024-08-08 · $28
  • Meals for Enhertu · 2024-07-10 · $29
  • Meals for Enhertu · 2024-06-27 · $8
  • Meals for Injectafer · 2024-02-29 · $7
Janssen BiotechErleada$39
1 payment
  • Meals for Erleada · 2024-05-06 · $39
Rigel PharmaceuticalsRezlidhia$29
1 payment
  • Meals for Rezlidhia · 2024-05-15 · $29
CelgenePomalyst$26
1 payment
  • Meals for Pomalyst · 2024-01-17 · $26
E.R. Squibb & Sons L.L.C.Opdivo$26
1 payment
  • Meals for Opdivo · 2024-05-23 · $26
EisaiLenvima$25
1 payment
  • Meals for Lenvima · 2024-07-01 · $25
Merck Sharp & DohmeKeytruda$24
1 payment
  • Meals for Keytruda · 2024-05-21 · $24
Gilead SciencesNone$21
1 payment
  • Meals · 2024-01-11 · $21
Takeda Pharmaceuticals U.S.A.Ninlaro$20
1 payment
  • Meals for Ninlaro · 2024-05-02 · $20

2023: $197

Payments by company in 2023
Daiichi SankyoEnhertu$44
2 payments
  • Meals for Enhertu · 2023-11-27 · $30
  • Meals for Enhertu · 2023-10-27 · $14
Merck Sharp & DohmeKeytruda$32
1 payment
  • Meals for Keytruda · 2023-11-20 · $32
AmgenEvenity$29
1 payment
  • Meals for Evenity · 2023-08-17 · $29
SeagenTukysa$28
1 payment
  • Meals for Tukysa · 2023-10-16 · $28
PharmaEssentia USABesremi$24
1 payment
  • Meals for Besremi · 2023-06-13 · $24
CelgenePomalyst$23
1 payment
  • Meals for Pomalyst · 2023-11-29 · $23
Pharmacyclics LLC An AbbVieImbruvica$19
1 payment
  • Meals for Imbruvica · 2023-11-13 · $19

Professional record

NPI
1255954988
Licence
CA 58377California G58377: Cancelled
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Physician assistant (363A00000X)
Mailing address
5725 W Las Positas Blvd Ste 100a, Pleasanton, CA, 94588
NPI first listed
2020-05-28
NPI last updated
2024-06-19
NPI record certified
2024-06-19

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 8611 Beverly Ln, Dublin, CA, 94568